A lung cancer drug (ramucirumab) currently being tested by Eli Lilly and Co., has been raking in positive results from a late-phase patient trial. The announcement has led to an initial 3 percent bump in Lilly's pre-market share prices, as well as renewed hope for cancer patients.
